EVM
HAE icon

Eaton Vance Management’s Haemonetics HAE Stock Holding History

Eaton Vance Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$593K Sell
8,004
-3
-0% -$215 ﹤0.01% 1315
2022
Q2 		$522K Sell
8,007
-1,344
-14% -$79.5K ﹤0.01% 1364
2022
Q1 		$591K Sell
9,351
-405
-4% -$22K ﹤0.01% 1485
2021
Q4 		$517K Buy
9,756
+433
+5% +$26.4K ﹤0.01% 1326
2021
Q3 		$609K Sell
9,323
-389,861
-98% -$24.6M ﹤0.01% 1179
2021
Q2 		$26.6M Sell
399,184
-636,369
-61% -$45M 0.04% 396
2021
Q1 		$115M Buy
1,035,553
+78,498
+8% +$9.71M 0.17% 132
2020
Q4 		$114M Sell
957,055
-115,614
-11% -$12.4M 0.18% 124
2020
Q3 		$93.6M Buy
1,072,669
+136,643
+15% +$11.9M 0.17% 127
2020
Q2 		$83.8M Buy
936,026
+356,015
+61% +$36M 0.17% 128
2020
Q1 		$57.8M Buy
580,011
+317,460
+121% +$34.4M 0.14% 138
2019
Q4 		$30.2M Buy
262,551
+45,945
+21% +$5.56M 0.06% 265
2019
Q3 		$27.3M Buy
216,606
+12,731
+6% +$1.62M 0.06% 260
2019
Q2 		$24.5M Buy
203,875
+53,819
+36% +$5.3M 0.05% 274
2019
Q1 		$13.1M Buy
150,056
+145,582
+3,254% +$13.2M 0.03% 358
2018
Q4 		$448K Hold
4,474
– – ﹤0.01% 1013
2018
Q3 		$513K Sell
4,474
-149
-3% -$15.4K ﹤0.01% 1019
2018
Q2 		$415K Buy
4,623
+15
+0.3% +$1.27K ﹤0.01% 1040
2018
Q1 		$337K Buy
4,608
+15
+0.3% +$1.03K ﹤0.01% 1016
2017
Q4 		$267K Buy
4,593
+29
+0.6% +$1.53K ﹤0.01% 1070
2017
Q3 		$205K Buy
+4,564
New +$190K ﹤0.01% 1075
2017
Q1 		– Sell
-11,281
Closed -$453K – 1041
2016
Q4 		$453K Sell
11,281
-8,165
-42% -$308K ﹤0.01% 875
2016
Q3 		$704K Buy
+19,446
New +$668K ﹤0.01% 785
2015
Q2 		– Sell
-4,526
Closed -$203K – 940
2015
Q1 		$203K Buy
+4,526
New +$189K ﹤0.01% 915

Other funds holding HAE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Eaton Vance Management's HAE Position: Q3 2022 in Review

Eaton Vance Management reduced its Haemonetics (HAE) stake by 0.04% in Q3 2022, selling an estimated $215 and leaving 8,004 shares worth $593K. The position accounts for ﹤0.01% of the portfolio, ranked #1315.

Eaton Vance Management first reported a position in HAE in Q1 2015 and has held it in 24 quarters since. The position peaked at $115M in Q1 2021. 268 funds tracked by Wall St. Rank hold HAE as of Q3 2022.

  • Eaton Vance Management held 8,004 shares of Haemonetics worth $593K as of Q3 2022.
  • Eaton Vance Management sold 3 Haemonetics shares in Q3 2022, an estimated $215.
  • Haemonetics made up ﹤0.01% of Eaton Vance Management's portfolio in Q3 2022, its #1315 holding.
  • Eaton Vance Management first reported a position in Haemonetics in Q1 2015 and has held it in 24 quarters since.
  • Eaton Vance Management's Haemonetics position peaked at $115M in Q1 2021.
  • 268 funds tracked by Wall St. Rank held Haemonetics as of Q3 2022.

Based on Eaton Vance Management's 13F filing for Q3 2022, filed 14 Nov 2022.